Can a cyclo-oxygenase type-2 selective tocolytic agent avoid the fetal side effects of indomethacin?

British Journal of Obstetrics and Gynaecology

Volumn 108, Issue 3, 2001, Pages 325-326

  Locatelli, Anna ^b   Vergani, Patrizia ^a   Bellini, Primula ^a   Strobelt, Nicola ^a   Ghidini, Alessandro ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b Divisione Ostetricia Ginecologia   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; NIMESULIDE; RITODRINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FEMALE; FETOTOXICITY; HUMAN; OLIGOHYDRAMNIOS; PREMATURE LABOR; PRIORITY JOURNAL; TOCOLYSIS;

ADMINISTRATION, ORAL; ADULT; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; FEMALE; HUMANS; INDOMETHACIN; ISOENZYMES; MEMBRANE PROTEINS; OBSTETRIC LABOR, PREMATURE; OLIGOHYDRAMNIOS; PILOT PROJECTS; PREGNANCY; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; SULFONAMIDES; TOCOLYTIC AGENTS; TREATMENT OUTCOME;

EID: 0035093673     PISSN: 03065456     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0306-5456(00)00071-1     Document Type: Article

References (5)

1. Use of a cyclooxygenase type-2-selective non-steroidal anti-inflammatory agent to prevent preterm delivery
2. Efficacy of the selective prostaglandin synthase type 2 inhibitor nimesulide in blocking basal prostaglandin production and delaying glucocorticoid-induced premature labor in sheep
3. COX-2 inhibitors
4. Neonatal end-stage renal failure associated with maternal ingestion of cyclo-oxygenase-type-1 selective inhibitor nimesulide as tocolytic
5. Nimesulide and neonatal renal failure